Literature DB >> 17325894

Renal failure in multiple myeloma: incidence, correlations, and prognostic significance.

V Eleutherakis-Papaiakovou1, A Bamias, D Gika, A Simeonidis, A Pouli, A Anagnostopoulos, E Michali, T Economopoulos, K Zervas, M A Dimopoulos.   

Abstract

Renal failure (RF) is a common and severe complication of patients with multiple myeloma (MM). The purpose of our study was to assess the incidence of RF in a contemporary series of newly diagnosed patients with MM, its association with specific clinical and laboratory features, and its impact on patients' outcome. Over the last decade, 756 newly diagnosed symptomatic patients with MM were included in our database. Renal failure, defined as a serum creatinine >or= 2 mg/dl at the time of diagnosis, was seen in 21% of patients. Multiple parameters were associated with RF, but logistic regression analysis showed that RF was independently associated only with International Staging System and Bence Jones proteinuria. The presence of RF was associated with a trend for higher early death rate but with a similar response to primary therapy. The median survival of patients with RF was 19.5 months versus 40.4 months for patients without RF (p < 0.001). Several variables were associated with impaired survival by univariate analysis. When multivariate analysis was performed the independent variables were poor performance status, thrombocytopenia, advanced age, high LDH and elevated serum beta2 microglobulin but not high creatinine. When corrected for stage, renal failure had no impact on survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17325894     DOI: 10.1080/10428190601126602

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  48 in total

1.  Renal impairment in multiple myeloma: presenting features in different departments.

Authors:  Ni Li; Yongman Lv; Hongbing Zeng; Fan He; Ying Yao; Xiaofeng He
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

2.  The albumin and monoclonal protein ratio as prognostic marker for multiple myeloma in the era of novel agents.

Authors:  Katalin Kádár; Krisztina Wolf; Judit Tábori; István Karádi; Judit Várkonyi
Journal:  Pathol Oncol Res       Date:  2012-07       Impact factor: 3.201

3.  Onconephrology: An Evolving Field.

Authors:  Ala Abudayyeh
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

4.  Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.

Authors:  Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Grigoriy Rekhtman; Zvenyslava Masliak; Pawel Robak; Dixie-Lee Esseltine; Huaibao Feng; William Deraedt; Helgi van de Velde; Bertrand Arnulf
Journal:  Haematologica       Date:  2015-01-16       Impact factor: 9.941

5.  Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma.

Authors:  Donald Moore
Journal:  P T       Date:  2016-05

6.  Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.

Authors:  Dao-bin Zhou; Li Yu; Xin Du; Jie Jin; Zhen Cai; Fangping Chen; Xiaoyan Ke; Xiao Li; Depei Wu; Fanyi Meng; Huisheng Ai; Jingshan Zhang; Dena DeMarco; Nianhang Chen; Jay Mei; Jianmin Wang; Jian Hou
Journal:  Int J Hematol       Date:  2015-03-10       Impact factor: 2.490

7.  Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).

Authors:  Hannah Tessenow; Madlen Holzvogt; Bruno Holzvogt; Marc Andrea; Simone Heyn; Thomas Schliwa; Maik Schwarz; Thomas Zehrfeld; Cornelia Becker; Christian Pfrepper; Georg Nikolaus Franke; Rainer Krahl; Madlen Jentzsch; Sabine Leiblein; Sebastian Schwind; Marius Bill; Vladan Vucinic; Thoralf Lange; Dietger Niederwieser; Wolfram Pönisch
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-22       Impact factor: 4.553

8.  Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study.

Authors:  Abhijat Kitchlu; Eric McArthur; Eitan Amir; Christopher M Booth; Rinku Sutradhar; Habeeb Majeed; Danielle M Nash; Samuel A Silver; Amit X Garg; Christopher T Chan; S Joseph Kim; Ron Wald
Journal:  J Natl Cancer Inst       Date:  2019-07-01       Impact factor: 13.506

9.  Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.

Authors:  Kevin W Finkel; Eric P Cohen; Anushree Shirali; Ala Abudayyeh
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

10.  The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Authors:  Meletios Dimopoulos; Adrian Alegre; Edward A Stadtmauer; Hartmut Goldschmidt; Jeffrey A Zonder; Carlos M de Castro; Zvenyslava Masliak; Donna Reece; Marta Olesnyckyj; Zhinuan Yu; Donna M Weber
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.